

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF MASSACHUSETTS

PROGENICS PHARMACEUTICALS, INC.,	)	
et al,	)	
	)	
Plaintiffs	)	
	)	CA No. 24-10437-PBS
-VS-	)	Pages 1 - 66
	)	
MIM SOFTWARE INC.,	)	
	)	
Defendant	)	

**MOTION HEARING BY VIDEO**

BEFORE THE HONORABLE PATTI B. SARIS  
UNITED STATES DISTRICT JUDGE

United States District Court  
1 Courthouse Way  
Boston, Massachusetts 02210  
October 8, 2024, 10:06 a.m.

LEE A. MARZILLI  
OFFICIAL COURT REPORTER  
United States District Court  
1 Courthouse Way, Room 7200  
Boston, MA 02210  
leemarz47@gmail.com

1 A P P E A R A N C E S:

2 MICHAEL J. BUNIS, ESQ. and ANITA M.C. SPEITH, ESQ.,  
3 Choate, Hall & Stewart, Two International place,  
4 100-150 Oliver Street, Boston, Massachusetts, 02110, for the  
5 Plaintiffs.

6 ALEXIS COHEN, ESQ., Wilmer Cutler Pickering Hale and  
7 Dorr LLP, 2100 Pennsylvania Avenue, N.W., Washington, DC,  
8 20037, for the Defendant.

9 LISA J. PIROZOLLO, ESQ., Wilmer Hale LLP,  
10 60 State Street, Boston, Massachusetts, 02109, for the  
11 Defendant.

12 MARIA R. BUTLER, ESQ., Thompson Hine LLP,  
13 Two Alliance Center, 3560 Lenox Road LE, Suite 1600,  
14 Atlanta, Georgia, 30326, for the Defendant.

15 JESSE JENIKE-GODSHALK, ESQ., Thompson Hine LLP,  
16 312 Walnut Street, Suite 2000, Cincinnati, Ohio, 45202, for  
17 the Defendant.

18 JEFFREY C. METZCAR, ESQ., Thompson Hine LLP,  
19 Austin Landing 1, 10050 Innovation Drive, Suite 400, Dayton,  
20 Ohio, 45342-4934, for the Defendant.

21  
22  
23  
24  
25

P R O C E E D I N G

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

THE CLERK: Good morning, Judge.

THE COURT: Good morning.

THE CLERK: So I have both sides on, so I'll call the case.

THE COURT: Thank you.

THE CLERK: The Court calls Civil Action 24-10437, Progenics Pharmaceuticals Inc. et al v. MIM Software, Inc. Could counsel please identify themselves.

MR. BUNIS: Your Honor, Michael Bunis for the plaintiff, Progenics, and with me is my partner, Anita Spieth, also on behalf of Progenics.

MS. PIROZOLLO: This is Lisa Pirozollo on behalf of Defendant MIM Software, Inc., and with me are Alexis Cohen, Marla Butler, Jesse Jenike-Godshalk, and Jeff Metzcar, who have been admitted pro hac vice. Ms. Butler and Ms. Godshalk and Mr. Metzcar are from the firm of Thompson Hine.

THE COURT: Thank you. So are you dividing up the argument among different lawyers, or is just one person going to argue for each side?

MR. BUNIS: Your Honor, again, Michael Bunis here. I'll be handling the 101 eligibility subject matter for the motion today, and Ms. Spieth will be handling the 12(b)(6) issues that are also on the docket today.

1 THE COURT: Thank you.

2 MS. PIROZOLLO: And we are similarly dividing  
3 with the Court's permission. This is Lisa Pirozollo. I  
4 will do the 101 issues, and Ms. Butler will do the motion to  
5 dismiss based on plausibility of the infringement claim.

6 THE COURT: Fine. So I shouldn't admit this to  
7 you all, but I have the morning for you, and I am finding  
8 this case extremely difficult because there are so many  
9 patents. Is this what's known as a "patent thicket"?

10 MR. BUNIS: We would say "no," your Honor.

11 THE COURT: Well, I don't understand. I mean, I  
12 haven't spent the time, obviously, you have spent with it,  
13 but I don't understand really the difference between all of  
14 them, and I am -- let me just start with basics -- I am not  
15 going to look at each of the seven patents because it would  
16 take me the rest of the year to do that. So I am looking  
17 for a shortcut, if that's the pejorative way of referring to  
18 it, like one patent or two patents that would settle this  
19 case, or would at least move it to Step B. And I think we  
20 sent that message out to you earlier this week that I --  
21 *Alice* is a very difficult case, very difficult, and I have  
22 written about it, and I've struggled with it. It takes a  
23 lot of analysis to get through seven patents, never mind  
24 just one, and, similarly, on a motion to dismiss at an early  
25 stage before I don't even understand the technology. So

1 you're asking a lot of one session to deal with seven patents.  
2 Let's just start there.

3 So I would like to ask perhaps on the motion to  
4 dismiss, is there one from each side, maybe take one patent  
5 that might settle this or might resolve it so I could decide  
6 whether I can do discovery on this case?

7 MS. BUTLER: So, your Honor, Marla Butler for MIM,  
8 who obviously we brought the motion. And I think the issue  
9 with the plausibility on the 12(b)(6) for failure to state a  
10 claim is that, you know, while we could have made arguments  
11 as to all seven of these patents, we did choose the three  
12 very purposefully where we think the failure to sufficiently  
13 allege infringement is the most egregious. And we didn't  
14 try to identify multiple elements within the three patents  
15 where we think that failure exists, but we identified one  
16 element in each of those three patents. And I think, as  
17 we've talked through this, I'd be in a position to explain  
18 this to the Court as to why, even without a deep understanding  
19 of the technology --

20 THE COURT: Well, maybe, maybe not. I am just  
21 frustrated. I am one session, and I don't want to deal with  
22 seven patents. So I think who -- I forget -- Ms. Pirozollo,  
23 who's from Hale and Dorr, Bill Lee used to be great at this,  
24 which is, like, what's the one thing that would settle this  
25 case, or at least get it to Step B where I think there's

1 enough there for discovery? And it would be useful for you  
2 all to flag that for me because otherwise you'll be here for  
3 a year while this is pending analysis. And unlike most  
4 cases, no one has given me a tutorial on even the technology  
5 or pictures or slides, nothing. I mean, you're expecting me  
6 to sit and read through seven patents in a timely way. So  
7 as you can sense the frustration, I have not had someone do  
8 this to me in a really long time.

9           So I'm going to start off on the motion to  
10 dismiss, and I'm going to ask you, Mr. Bunis, to start off  
11 with what do you think -- explain to me these patents and  
12 this patent thicket, as far as I'm concerned. Which is the  
13 one that's going to be the crumbs that will bring me through  
14 the forest?

15           MR. BUNIS: Well, let me start by saying,  
16 obviously it's not our motion.

17           THE COURT: I understand, but --

18           MR. BUNIS: But we are perfectly comfortable using  
19 one of the patents. We think that the '817 patent, which is  
20 a later-filed patent, is helpful, but I'm more than happy to  
21 use one of the patents from the earlier family of patents.  
22 And Ms. Pirozollo selected the '346. I'm happy to use the  
23 '346. But the Court has to keep in mind, Judge, and I know  
24 you will, that it's not just Claim 1 when evaluating  
25 eligibility under *Alice*; you have to look at all of the

1 claims, and that's very --

2 THE COURT: Which one is it, from your point of  
3 view? You think if I get my way through '346 --

4 MR. BUNIS: We would prefer that you use '141  
5 which is from the same family, Judge.

6 THE COURT: So you prefer '141.

7 Ms. Pirozollo, you're '346?

8 MS. PIROZOLLO: I suggested '346, and that is  
9 because of all the references to the specification. They  
10 have a common specification, and so our brief refers to the  
11 specification of the '346. So that's why we wanted to focus  
12 on that particular patent, because we do understand this is  
13 complicated, and we were trying to simplify things a little  
14 bit by focusing on that patent. I think the issues --

15 THE COURT: All right, so I will focus on '346.

16 Mr. Bunis, you want me to focus -- I want to give  
17 each side a chance -- you think '141 will do it?

18 MR. BUNIS: They share a common specification,  
19 Judge. I just want to make the conceptual point, and I know  
20 the Court is aware of this, that you can't just focus on one  
21 of the claims, in fact, just Claim 1 in '346; you need to  
22 look at all of the claims. And if we do that and the Court  
23 is open to all of that, then that's fine.

24 THE COURT: Well, all the claims within that  
25 patent?

1 MR. BUNIS: That's right.

2 THE COURT: Yes, yes. All right, so let's start  
3 on the 101, and then at some point, what do you think  
4 timewise? It's 10:10. Maybe 15 minutes a side? Is that  
5 enough, half an hour a side, and then we move to the motion  
6 to dismiss? What are you thinking?

7 MS. PIROZOLLO: I think a half an hour would be  
8 helpful, and I'll try to move through as quickly as possible  
9 and be shorter, if I can.

10 THE COURT: Shorter is not as key to me as  
11 understanding this.

12 MS. PIROZOLLO: I'll try to be clear, and, you  
13 know, I think half an hour would allow for you to interrupt  
14 me if I am not explaining clearly.

15 THE COURT: Okay. And would you call this a  
16 "patent thicket"?

17 MS. PIROZOLLO: I would agree that I don't see the  
18 difference between some of these claims in the invention,  
19 and we think that all these four patents that we've moved on  
20 are basically directed to the same thing.

21 THE COURT: Okay. All right, so you're the moving  
22 party, so go for it.

23 MS. PIROZOLLO: Okay, thank you, your Honor. So  
24 as you know, Alice Step One asks whether the claims are  
25 directed to an abstract idea. Here, the claims of the '346

1 patent clearly are. I'm going to discuss, first, the claims  
2 and the governing case law, and then I wanted to address  
3 under Step 1 Progenics' reliance on the fact that the claims  
4 require a 3D image to be created, and also Progenics'  
5 discussion of the *CardioNet* and *McRO* cases.

6 So the claims of the '346 patent are directed to  
7 analyzing --

8 THE COURT: Hold on a second. I want to just pull  
9 that out so I can mark up that patent.

10 Okay, I've got it here.

11 MS. PIROZOLLO: Okay. So the claims of the '346  
12 patent are directed, and we focused on representative  
13 Claim 1, of analyzing medical images to assess cancer risk  
14 and presenting the results of that analysis. And so, for  
15 example, if you look at Claim 1, there are the steps of  
16 accessing medical images. That's romanette i. Performing  
17 an analysis on the medical images using a machine-learning  
18 algorithm. That's romanette ii. And displaying or  
19 generating a report with the results of the analysis. That's  
20 romanette iii. So the claims are directed to obtaining  
21 medical images, analyzing them, and displaying the results  
22 of the analysis.

23 THE COURT: But can I just stop you. On Roman ii,  
24 I guess it is, it says "To generate the risk map --" so go  
25 through the whole thing, it's a risk map -- "wherein the

1 risk map comprises a visual representation of tissue  
2 overlaid with graphical denotations, marking one or more  
3 regions of risk of cancer or risk of recurrence of cancer."

4 Okay, all right, so I just wanted to -- it's not  
5 just an analysis. It's a specific kind of analysis?

6 MS. PIROZOLLO: Right. And the risk map under the  
7 patents is, it says "A risk map comprises a visual  
8 representation of tissue." And so what the risk map is,  
9 according to the patent, is a visual representation of bones  
10 and organs within a medical image.

11 THE COURT: But ones that are high-risk, right?

12 MS. PIROZOLLO: Well, what they do is they -- I'll  
13 back up because this is admitted by Progenics.

14 So doctors analyze two types of medical images to  
15 determine cancer risk: They analyze anatomical images,  
16 which are images like CAT scans which will show a patient's  
17 bones and organs, so they get the information of where the  
18 bones and organs are from the anatomical images.

19 They also have what are called "functional images,"  
20 and these are images like PET scans. And what the functional  
21 images show is, if the patient has taken a radio-  
22 pharmaceutical, that radiopharmaceutical will bind at places  
23 where cancer might be occurring, and the functional image  
24 will show where those locations are in the patient's body.  
25 And so physicians use both the anatomical image, so that

1 they know where the bones and tissue are, and the functional  
2 image, so they see where the radiopharmaceutical is bound to  
3 determine the cancer risk.

4 So this claim is talking about -- although it  
5 doesn't specify the medical images in the claim, it's  
6 talking about using a machine-learning algorithm to create a  
7 visual representation of bones and tissue. So that's, you  
8 know, the anatomical image, and then using that to identify  
9 geographic locations of where radiopharmaceuticals are bound.

10 THE COURT: It's the overlay, right?

11 MS. PIROZOLLO: Yes, yes. And that's why in  
12 Progenics' brief they emphasize the 3D visualization or the  
13 risk -- the 3D image that's in the "wherein" clause at the  
14 top of Column 36 as the innovation of their -- one of the  
15 innovations of this claim.

16 THE COURT: So 3D is the inventive step under step  
17 two? Is that what it would be?

18 MS. PIROZOLLO: Well, what they say, although we  
19 disagree with it, is that the 3D image in the "wherein"  
20 clause, which is a "wherein" clause describing step two, is  
21 an innovation. But if the Court has its bearings on the  
22 claim, I can walk through why we still think this is an  
23 abstract idea.

24 THE COURT: It would be useful for me to actually --  
25 because this is the real problem with 101 analyses: Usually

1 I get taught during the *Markman* hearing, and no one has  
2 taught me yet. So it's very helpful to have you both walk  
3 through the claims. Don't assume too much knowledge about  
4 anything.

5 MS. PIROZOLLO: Okay. I must say, you know, in  
6 the 101 case law, you know, the Federal Circuit has noted  
7 that even though claims are very long and complicated, that  
8 doesn't mean they still can't be directed to an abstract  
9 idea, so --

10 THE COURT: I get that, but I have to understand  
11 it in my gut first, okay?

12 MS. PIROZOLLO: Yes. With that in mind, what this  
13 claim is directed to is using machine learning to analyze  
14 medical images, which can include these anatomical and  
15 functional images, to identify cancer risk, and then  
16 displaying the results on a graphical user interface to  
17 patients.

18 But, of course, numerous cases, as you know, say  
19 just using automating activity that doctors performed  
20 historically is not patentable and is an abstract idea.  
21 And, of course, that was the issue in *Alice* where the claim  
22 was directed to intermediated settlements, and the court  
23 said adding the words "apply it with a computer" is not  
24 enough. And we've cited other cases in our brief that stand  
25 for that proposition that automating activity that had been

1 performed by humans is not enough. We cited *Credit*  
2 *Acceptance* and the *Voter Verified* case. And we think the  
3 logic of those cases, you can't just add "do it on a  
4 computer" or "do it with machine learning" to activity  
5 humans did and have that be a patentable idea. That's an  
6 abstract idea, and I want to explain why we think that logic  
7 applies here.

8 As Progenics concedes -- and this is where I'd  
9 like to explain why we think you can find, on the basis of  
10 this record, that what Progenics is doing is trying to  
11 patent the use of machine-learning analysis to do what  
12 doctors already have done for a long time, because doctors  
13 have already analyzed medical images and located bones and  
14 tissue and used that analysis to identify cancer risk. And  
15 where this is clear in the record is, for example, in the  
16 specification of the '346 patent. So you look at Column 2  
17 of the specification where Progenics --

18 THE COURT: I'm getting there. I'm getting there.

19 MS. PIROZOLLO: Okay. And it's, you know, it's  
20 most of Column 2, so I'll summarize. But what Column 2 is  
21 describing in the background of the invention is how doctors  
22 previously identified cancer risk and communicated those  
23 results to patients. And what that column makes clear is  
24 that it has a lengthy discussion about how physicians  
25 analyzed medical images, created reports of that analysis,

1 and presented the results of that analysis to patients,  
2 including assessment of cancer risk.

3 We also think the Second Amended Complaint makes  
4 clear --

5 THE COURT: Excuse me. Is there anywhere in  
6 Column 2, or elsewhere in the specification, that talks  
7 about this overlay? In other words, was there a capability  
8 of doing that before where --

9 MS. PIROZOLLO: Like -- yes, so what --

10 THE COURT: -- I don't know, collate or combine  
11 the results of the anatomical and the functional?

12 MS. PIROZOLLO: Yes. The specification refers to  
13 machines -- and I'll try to find the cite -- that would take  
14 in proximity a CAT scan and a PET scan. So that technology  
15 was known.

16 In addition, I would direct you to Progenics'  
17 Second Amended Complaint at Paragraphs 19 to 21 in which  
18 Progenics describes how doctors used anatomical and  
19 functional images. And in Paragraph 21 of the Second  
20 Amended Complaint, Progenics specifically says that a  
21 physician would use a combination of a CAT scan and a PET  
22 scan. So the idea of using both --

23 THE COURT: I'm looking through the complaint, and  
24 I just want to make sure. 19 to 21, is that what you're  
25 relying on?

1 MS. PIROZOLLO: Yes. And in particular, in  
2 Paragraph 21, Progenics refers to a combination of a CAT  
3 scan and a PET scan.

4 THE COURT: So 21 to 22 explain, though, that it  
5 was different beforehand. Am I looking at the right  
6 paragraphs?

7 MS. PIROZOLLO: Well, Paragraphs 20 to 21 are  
8 describing the traditional process for analyzing medical  
9 imaging. So this was before --

10 THE COURT: So you had two scans, one in each hand  
11 kind of thing, and the doctor would interpret, like, "Oh,  
12 here is where the risk of cancer is, here's where the tumors  
13 are, here's the organ," right? And then they would in their  
14 mind integrate the two?

15 MS. PIROZOLLO: Yes. They would use a combination.  
16 But, you know, doctors -- and I found the cite in the '346  
17 specification -- I don't mean to make you jump around but --

18 THE COURT: No, that's okay. I'm here to learn.  
19 I'm here to learn. Go ahead.

20 MS. PIROZOLLO: At Column 27, there's a reference  
21 to "PET-CT scanner instruments common in many hospitals."  
22 So not only did doctors use both types of images, but the  
23 idea of, you know, combining those images to do the analysis  
24 was known.

25 THE COURT: Now, where are you looking at? What

1 column?

2 MS. PIROZOLLO: It's Column 27.

3 THE COURT: Line?

4 MS. PIROZOLLO: Lines 1 through 10.

5 THE COURT: Good, okay.

6 MS. PIROZOLLO: So it says, "In certain embodiments,  
7 composite images comprising CAT scans overlaid with PET scans  
8 are obtained using dedicated PET-CT scanner instruments  
9 common in many hospitals."

10 THE COURT: But that's embodiments of the patent,  
11 right, not prior?

12 MS. PIROZOLLO: Yes, it is, but I'm referring you  
13 to the PET-CT scanner instruments that were common in  
14 hospitals.

15 THE COURT: It doesn't say that here, right?

16 MS. PIROZOLLO: Yes. It says --

17 THE COURT: The fusion to create the composite  
18 image --

19 MS. PIROZOLLO: It doesn't use the words "fusion"  
20 and "composite," that is true.

21 THE COURT: Okay, all right.

22 MS. PIROZOLLO: But I'm going to actually get to  
23 that under the case law. You know, creating different types  
24 of visualization of data is an abstract idea under the case  
25 law, so manipulation of data --

1 THE COURT: All right, go ahead. I keep  
2 interrupting you because I'm learning, but go ahead.

3 MS. PIROZOLLO: Okay. So I wanted to direct you  
4 to the Second Amended Complaint which talks about how  
5 doctors use both types of medical images to identify cancer  
6 risk. And I'd also direct you to Progenics' opposition  
7 brief at Page 10 which talks about how doctors use both of  
8 these types of medical images to identify cancer risk.

9 So it's also undisputed with these claims that the  
10 claims only rely on generic computer equipment. So, you  
11 know, we were looking at Claim 1 of the '346 patent, and the  
12 reference there is only to a generic computer processor and  
13 memory. So there are no specifics in these claims about  
14 computer technology.

15 And so under *Alice* and the other cases we've  
16 cited, such as *Credit Acceptance* and *Voter Verified* and many  
17 others, just using generic computer equipment to automate  
18 activity historically performed by humans doesn't make an  
19 abstract idea patentable. So here all the claims are doing  
20 is automating this analysis of different types of medical  
21 images using generic computer equipment.

22 The claims do have a reference to machine learning,  
23 but they do not specify anything about that machine learning.

24 THE COURT: Is machine learning essentially AI?

25 MS. PIROZOLLO: Yes. In the spec, yes, that's my

1 understanding. In the spec, the only description of machine  
2 learning is convolutional neural networks and ANN, which is  
3 another type of neural network. So there's a generic  
4 description of kind of AI in the spec, but no specific  
5 improvement, or certainly not claimed, and also not described  
6 in the specification.

7 So that's our basic argument as to why these  
8 claims are taking the analysis of medical images and  
9 automating it, which is not patentable under *Alice*.

10 And I wanted to address two specific arguments  
11 Progenics is making to rebut that argument: one, Progenics'  
12 reliance on the 3D image that's referenced in the "wherein"  
13 clause, and Progenics' reliance on the *CardioNet* and *McRO*  
14 cases.

15 So Progenics in its opposition to our motion  
16 repeatedly characterizes 3D visualization as a specific,  
17 concrete solution that is patentable under 101, but the  
18 Federal Circuit has rejected similar arguments and held that  
19 claims requiring certain types of visualization or  
20 manipulation of data are abstract, and there are two cases I  
21 wanted to highlight on that point.

22 First, in the *Trading Technologies* case, which was  
23 about providing information to traders, the Federal Circuit  
24 held that providing a trader with additional financial  
25 information to facilitate market trades was abstract. And

1 in that case, the patentee made similar arguments to the  
2 ones Progenics is making here, arguing that the invention  
3 provided a particular graphical user interface that improves  
4 usability, visualization and efficiency; and that was the  
5 innovation in the claims. But the Federal Circuit rejected  
6 those arguments and held the claims were still just directed  
7 to a process of gathering, analyzing information and  
8 displaying results, and not any inventive technology for  
9 performing those functions. And that is also the case with  
10 Progenics' claims, which don't have any inventive technology  
11 for performing the claimed functions.

12 The Federal Circuit reached a similar result in  
13 the *AI Visualize* case which we've cited in our brief, which  
14 involved, appropriately, patents relating to the  
15 visualization of medical scans. And in *AI Visualize*, much  
16 like Progenics argues here, the patentee argued that the  
17 claims weren't directed to an abstract idea because they  
18 required, quote, "creation" of virtual views of medical  
19 images on the client's computer. And the Federal Circuit  
20 rejected that argument and invalidated the patent under 101,  
21 holding that the creation of a virtual view from existing  
22 data was simply abstract data manipulation, and that's at  
23 Page 1,379 of the *Trading Technologies* case.

24 So the logic of *Trading Technologies* -- Progenics  
25 has highlighted this 3D visualization as the key innovation

1 of its patents, but *Trading Technologies* and *AI Visualize*  
2 both teach that creation of a 3D visualization of data  
3 contained in medical images is simply data manipulation,  
4 which is abstract under the case law.

5 THE COURT: Excuse me. Did either of them involve  
6 3D?

7 MS. PIROZOLLO: The virtual view may have. I --

8 THE COURT: Okay, don't worry about it. Don't  
9 worry. I'm just starting to roll up my sleeves.

10 MS. PIROZOLLO: I --

11 THE COURT: What does 3D mean? I have this image  
12 of, you know, the thing at the airport where you see a human  
13 being, you know what I mean, when you walk in?

14 MS. PIROZOLLO: A holograph.

15 THE COURT: A holograph, right. Does something  
16 pop up, and you know exactly where the cancer is, a big red  
17 spot? Or is this just something turning on screen?

18 MS. PIROZOLLO: It's just 3D, three-dimensional.  
19 And it's worth noting that CAT scans and PET scans are  
20 three-dimensional. So the medical images that you start  
21 with here are three-dimensional, so there's no magic to a 3D  
22 image. And even if there were, creating a 3D visualization  
23 isn't patentable under the 101 case law from the Federal  
24 Circuit.

25 THE COURT: So 3D means if you're, like -- well,

1 maybe I'll ask, something I can see here. I mean, it's not  
2 a flat picture but it's -- I'm just trying to figure out how  
3 you see that on screen. Maybe -- what does it even look  
4 like? It's not 3D --

5 MS. PIROZOLLO: If you look at Figure 4 of the  
6 patent, obviously it is 2D, but I think it gives you an idea  
7 of what they say their invention would show. So you can  
8 imagine looking at Figure 4 on a computer screen and seeing  
9 the bones of the patient and --

10 THE COURT: Okay, well, this doesn't really show  
11 it, but, in any event -- okay, thank you.

12 MS. PIROZOLLO: So I would like to move on, if  
13 it's okay with the Court, to talking about the *CardioNet* and  
14 *McRO* cases because --

15 THE COURT: You can if you want, but I really --  
16 this is why I love having lawyers -- I should have had you  
17 come in person, you're both local -- because I love having  
18 people explain the technology and walk me through the parts  
19 of the patent that you find important. I'll give you a few  
20 minutes on it, but then I was wondering how we should handle  
21 the -- you also wanted and Mr. Bunis wanted me to focus on  
22 the '141 as well, so I want to take time to do that. But  
23 you're welcome to spend a few minutes on it, and then  
24 I'll -- I think probably we should -- are you prepared to  
25 address '141?

1 MS. PIROZOLLO: So I can make very quickly a  
2 couple of additional points.

3 THE COURT: Okay.

4 MS. PIROZOLLO: So I want to just make the point,  
5 because it's important if you review the *CardioNet* cases and  
6 *McRO* cases because Progenics argues that its patents have  
7 the rule-based way of analyzing medical images that takes  
8 them out of 101. And I actually can be brief and point you  
9 to -- well, I will say, if you look at the claims -- and  
10 we've looked at Claim 1 of the '346 patent, and this will be  
11 the same in Claim 1 of the '141 patent -- there are no rules  
12 in those claims for how you analyze medical images. There  
13 are no descriptions of specific things to look at in the  
14 medical image to determine cancer risk. So this is not a  
15 case where the claims themselves set forth rules, which  
16 could be patentable under cases like *CardioNet* and *McRO*.

17 And in fact at Page 10 of Progenics' brief,  
18 Progenics actually says what they mean when they say the  
19 claims are "rules-based." They say "Rules based," and then  
20 they have the parenthetical that says "e.g., machine  
21 learning based.)" So what Progenics is saying is, these  
22 claims have a rules-based analysis of medical images because  
23 we have the instruction to use machine learning. But the  
24 Federal Circuit has -- that's just like "apply it with a  
25 computer." That is not -- just saying "use machine

1 learning" is not setting forth specific rules or technological  
2 improvements. That's just invoking the use of generic  
3 computer technology to perform the analysis. And that is  
4 very different from cases like *CardioNet* and *McRO*, which  
5 have had, you know, very specific ways of, in *McRO*,  
6 lip-syncing, and in *CardioNet*, diagnosing heart arrhythmias,  
7 atrial fibrillation, and atrial flutter.

8 So I would just add --

9 THE COURT: We need to -- we're getting close to  
10 the half an hour, so --

11 MS. PIROZOLLO: Okay, all right.

12 THE COURT: So maybe I'll move to Mr. Bunis, who  
13 can both respond to you and then perhaps flag the one you  
14 want me to focus on. Does that make some sense? And then  
15 I'll give you rebuttal time?

16 MS. PIROZOLLO: That sounds fine. Thank you, your  
17 Honor.

18 THE COURT: Thank you.

19 MR. BUNIS: Your Honor, forgive me. I think I got  
20 a cold last night, and if you can't hear me very well,  
21 please let me know, but hopefully I'm coming through loud  
22 and clear.

23 THE COURT: I hope you're feeling better.

24 MR. BUNIS: Thank you.

25 THE COURT: I hope it isn't the big C.

1 MR. BUNIS: Yeah, I hope not, absolutely.

2 Actually --

3 THE COURT: Maybe I'm glad you're doing it on  
4 Zoom, huh?

5 MR. BUNIS: Judge, so obviously, as Ms. Pirozollo  
6 mentioned, the plaintiffs believe that you don't have to get  
7 passed out of Step 1 in order to find these patents  
8 patent-eligible, and let me help you with that. These  
9 claims, whether you use the '346, the '141, the '817,  
10 et cetera, all direct you to a multistep, very detailed  
11 process that is a practical solution to a technical problem  
12 that existed before, and let me explain.

13 So the patient who is suffering from cancer will  
14 have different kinds of scans performed. Those scans, as  
15 Ms. Pirozollo mentioned, include things like a CAT scan. It  
16 can also include a PET scan. As Ms. Pirozollo said, the CAT  
17 scan is what's referred to in the patent as an "anatomical  
18 image." The PET scan is referred to as a "functional image."

19 What happens when that patient in the prior art  
20 goes to see the doctor is that the radiologist reads those  
21 images and makes determinations about the state of the  
22 cancer, the treatment plan, the progression of the cancer,  
23 et cetera, all based on, as the Court was saying -- I think  
24 I was interpreting -- for comparing in the one instance the  
25 functional image and the anatomical image; and, of course,

1 using her own subjective experience as a radiologist in  
2 saying, "Here is where I believe the boundaries are. Here  
3 is where the segmentation occurs. Here is where the tissue  
4 is. Here is where the organ is." And as a result, they  
5 make determinations about treatment plans, staging cancer,  
6 et cetera.

7 Now, in Massachusetts we're lucky, right? You can  
8 go to the Dana Farber, and the likelihood is that you're  
9 going to find a radiologist that is experienced and knows,  
10 when they see an artifact on a particular scan, "Oh, I know  
11 that, I've had experience with that," and they can make  
12 determinations based on their experiential review of these  
13 functional and anatomical images.

14 That created a problem, of course. The problem  
15 was that if you weren't lucky enough to be located where a  
16 radiologist had a ton of experience, but you were in a place  
17 or just happened to be that you got a radiologist who didn't  
18 have that much experience -- and, by the way, it's not only  
19 based on experience -- I'll come back to that -- you were at  
20 the mercy of the reading of those functional and anatomical  
21 images by the radiologist. That was subject to recency  
22 bias. It was subject to all different things in addition to  
23 just the number of images or scans that a particular  
24 radiologist may have read in the course of her career.

25 Here, with this invention, in this multistep

1 process, what the patent's claim is, "a process by which the  
2 images of the patient are reviewed." Then --

3 THE COURT: Can we stop off on the comparison one?

4 MR. BUNIS: Sure.

5 THE COURT: So Ms. Pirozollo said that those,  
6 though, are typically 3D, or can be 3D. Let's put it that  
7 way.

8 MR. BUNIS: Yeah, the display of the image, I  
9 think what you might -- I don't know if you've ever had this  
10 experience, but you very often look at a CT image or a  
11 functional image on a radiologist's computer where they can  
12 manipulate it. And so by 3D, I think the Court should keep  
13 in mind that you can see volumes, right? They're represented  
14 in the 2D image, which can't hold the volume, but it's a  
15 representation of volume more than just in two dimensions,  
16 so that you can see, for example, the depth of the cancer  
17 within the tissues, et cetera.

18 THE COURT: I see.

19 MR. BUNIS: Right? Does that answer the Court's  
20 question?

21 THE COURT: Yes, so it's --

22 MR. BUNIS: It's a 3D representation of something  
23 that's --

24 THE COURT: But I guess the key point is, it did  
25 preexist?

1           MR. BUNIS: Well, yes, 3Ds did exist defined for  
2 CT and defined for functional, but as -- I can continue in  
3 explaining --

4           THE COURT: Yes, keep going. So what you're  
5 saying is, it didn't, 3D, exist for composite?

6           MR. BUNIS: Yes, that's right, but let me explain  
7 how it works, if I can.

8           THE COURT: Yes, go for it.

9           MR. BUNIS: So in the patent claim, the claim  
10 discusses the collection of the images for that patient,  
11 right? In particular, the anatomical images. Then the  
12 machine learning is applied. This convolutional neural  
13 network is applied to those images.

14           And, your Honor, you should think of that as a  
15 very distinct rule set that has the benefit of an algorithm  
16 that's been trained in looking at thousands of previous CT  
17 images, CT scans. And rather than having an inexperienced  
18 radiologist, you now have an algorithm that can make  
19 judgment calls.

20           THE COURT: But who sets the algorithm?

21           MR. BUNIS: The algorithm is set by the  
22 convolutional neural network that is used and claimed in the  
23 patent.

24           THE COURT: I don't know what that -- sorry. Is  
25 it something that is in the patent that sets the rule?

1           MR. BUNIS: The patent discloses in claims the use  
2 of machine learning and describes in the embodiments that  
3 that machine learning is a convolutional neural network.

4           THE COURT: I don't know what that is.

5           MR. BUNIS: Well, it's a particular application of  
6 machine learning. And what it means for these patents,  
7 Judge, is that the model, the algorithm has been trained by  
8 looking at thousands of CT images in the past, and, like an  
9 experienced radiologist, can make logical judgment calls  
10 about the placement of that segmentation, about where the  
11 map should exist on that particular patient.

12           THE COURT: But just to answer my question really  
13 directly, it isn't your client that trained AI, right? It's  
14 been trained by -- I don't know whether iRobot did it, but  
15 not your people? I mean, it was written by some other  
16 people?

17           MR. BUNIS: Well, make no mistake: Convolutional  
18 neural networks did exist before. They were not used in  
19 connection with reading of images in this way at the date of  
20 the filing of the patent, but the patent is using the logic,  
21 the rules of that machine learning, of those convolutional  
22 neural networks, to make those judgment calls in reading the  
23 anatomical image of the patient. And then it uses the  
24 anatomical image and the functional image and produces that  
25 3D map, right, that risk map, which your Honor was correct

1 in pointing out, in focusing initially on the generation of  
2 that thing which did not exist before. And it produces  
3 something which has the benefit of the evaluation of the  
4 patient scan and the application through the patient scan of  
5 that machine-learning logic to create something that never  
6 existed before.

7           And that is the solution. That is the technical  
8 solution to the industry problem that these patents were  
9 solving. And that's why a patient who is in a place where  
10 you may not -- I don't want to cast aspersions on  
11 geography -- but in a place where you may not find a  
12 radiologist with that much experience, now, by virtue of  
13 these inventions, the determinations about where the risk  
14 map and where the overlays are, or where the cancer is and  
15 the treatment plan, has the benefit of the most experienced  
16 of radiologists. It lowers the playing field.

17           Now, the multistep process creates something that  
18 never existed before, but in doing so, it uses an automation.  
19 Now, the Federal Circuit has been very clear that when you  
20 incorporate an automation, when you incorporate, for  
21 example, a known algorithm or mathematical formula into a  
22 multistep process, that doesn't render it patent ineligible,  
23 and I would point the Court to *Diamond v. Diehr*. In the  
24 *Diehr* case, Judge --

25           THE COURT: That old, old case?

1           MR. BUNIS: That's right, Judge. In that case,  
2 the patent was directed to a process I think for curing  
3 rubber, and one of the steps in the process used a  
4 particular mathematical formula. And I don't know the name  
5 of the formula; it begins with an A. But, anyway, the Court  
6 said specifically, simply because the claim and the process  
7 incorporated a step of a known formula, that doesn't render  
8 it ineligible. That's the same thing that's going on here,  
9 and so that's what the claims are directed to.

10           Now, with respect to the 3D visualization, Judge,  
11 the Federal Circuit in both the *CardioNet* case and in the  
12 *McRO* case -- and *McRO* is very relevant here, it's extremely  
13 relevant -- what they said was: You should be careful not  
14 to presume that the patent is claiming the automation of  
15 what the prior art previously did.

16           Now, in the *McRO* case, what they're talking about  
17 there is sort of a technology directed to lip-syncing and  
18 the creation of models around when certain sounds are formed  
19 in the face. It wasn't doctors there. It was artists who  
20 actually created 3D manipulations, and they did it by art,  
21 right? They did it by saying, "Oh, I know when you make the  
22 O sound what the face looks like, and so I create the lips  
23 to do a certain thing," right?

24           And in the *CardioNet* case, it was doctors. They  
25 said, "Oh, I can make a judgment call about when I see a

1 particular flutter or a particular rhythm, and I can make a  
2 judgment call."

3 And in both of those cases, the court said that  
4 was sufficient. And in the *McRO* case, the output of those  
5 determinations that were done automatically was a 3D  
6 animation; no different, I would offer, your Honor, than the  
7 3D animation that is the output of the process that's claimed  
8 in these patents, right?

9 And in fact the court in *CardioNet* said that it  
10 didn't matter that it wasn't a tangible image, it didn't  
11 matter that it was a 3D image; that it was sufficient enough  
12 to move it away from simply automating a process that had  
13 previously been done in the prior art.

14 Now, doctors previously, as you pointed out in the  
15 very beginning, they had compared one to the other, right?  
16 But they had not previously used machine learning to create  
17 these overlays, these 3D risk maps, for the purposes of  
18 making diagnosis decisions involving cancer.

19 Now, I'm reluctant to move on, but I'll check in  
20 with the Court to make sure that that is sort of a practical  
21 understanding of what's going on here.

22 THE COURT: It is a practical understanding, but  
23 going into claims, Claim 1, so do you agree that really  
24 the -- I don't know whether it's Step 1 or Step 2 -- I find  
25 that piece of it impenetrable in the case law -- but whether

1 it's Step 1 or Step 2, that the issue here is the creation  
2 of a -- well, basically the "wherein" clause?

3 MR. BUNIS: Correct. That is correct, Judge. I  
4 do agree with you. I would say to you, Judge, that you have  
5 a multistep process that includes receiving an anatomical  
6 image of the patient. You apply to that anatomical image  
7 machine learning in the form of convolutional neural networks  
8 that makes this heretofore analysis, an analysis that had  
9 not been done but an analysis using thousands of previously  
10 read CT images, and then it considers the functional image,  
11 and it produces or generates that 3D map, right? It's a  
12 multistep process that uses a real tool.

13 Now, let me pause for a second. Judge, in the  
14 cases that the defendants cite where the Federal Circuit and  
15 other District Courts have found that the claims are drawn  
16 to abstract ideas, those claims all read data and then spit  
17 it out in another form. In other words, they just  
18 reformatted the data. And in fact the Court looked at this  
19 very same kind of thing in the *Ocean* case not too long ago.  
20 I'm reluctant to bring it all back to you, Judge, but there  
21 you were looking at patents related to metrology --

22 THE COURT: No, it's not bringing it back. It's  
23 blossoming as we speak. It's very much still -- I've got  
24 two *Ocean* cases now, so it's not bringing it back. But I do  
25 remember the analysis which I found so difficult, even in

1 that context, but what saved it were, at least two of them  
2 were dependent claims.

3 MR. BUNIS: Right. And you said in that case, you  
4 said, if you just look at collected data related to  
5 metrology and filter it, that's not good enough. That  
6 doesn't do it. That doesn't get you to -- I think you said  
7 the guillotine, the Alice guillotine. But what you found  
8 saved those dependent claims was that in the claims, they  
9 recited matters in which you could solve the problem that  
10 had previously been identified in the prior art.

11 Here, the problem in the prior art was that you  
12 couldn't get a reliable way to diagnose cancer that took  
13 advantage of, or at least weren't dependent upon, the  
14 relative experience of the radiologist who was making the  
15 determination. Here, by virtue of the application of the  
16 automation, of the machine learning or convolutional neural  
17 network, you get the benefit of all of that logic, those  
18 rules, right? And you create something with it that  
19 heretofore never existed, and that something was a 3D  
20 visualization.

21 Now, the defendants may say, well, now that's --

22 THE COURT: Can I jump in. So that's the '346. I  
23 think that's what it is. Yes. And you also wanted me to  
24 look at the, what was it, the --

25 MR. BUNIS: The '141. Judge, it's the very same

1 thing that's created in the '141 with nuances. The '141  
2 describes with specificity, for example, the type of scan  
3 that you're using. Ms. Pirozollo explained how in a  
4 functional image, you can have a radiopharmaceutical. And,  
5 again, you know, there's the situation -- perhaps the Court  
6 is familiar with it -- where the patient is injected with a  
7 particular substance that would bind to the cancer, and then  
8 on the back side of that substance there's a radionucleotide  
9 that lights up.

10 THE COURT: Yes.

11 MR. BUNIS: So those claims in the '141 include  
12 more detail around those examples or those embodiments in  
13 the invention. But the notion, conceptually it's all the  
14 same, and that is to say, you collect patient's images; you  
15 apply to those patient's images machine learning in the form  
16 of a convolutional neural network that has the benefit of  
17 having been trained on thousands of images to make  
18 determinations and judgment calls about where the map  
19 segmentation should be done; and then it produces an overlay  
20 that is that sedimentation that is smart, Judge. It is  
21 smarter than any radiologist --

22 THE COURT: So why are they different? I mean,  
23 I'm just trying to -- wouldn't one encompass the other?

24 MR. BUNIS: Well, no. They each have nuances.  
25 For example, in the '141 patent, there's descriptions of how

1 the 3D boundaries are placed within the risk map, which  
2 doesn't exist in the '346 patent.

3 THE COURT: Like where? Like where?

4 MR. BUNIS: Well, for example, in the "wherein"  
5 clause, there's a subclause (a) that says "Using the  
6 composite image to graphically identify the 3D boundary for  
7 each one or more of the regions of imaged tissue within the  
8 nuclear medicine image." It also describes the nuclear  
9 medicine image by name; yet it's calling it the functional  
10 image in the '346. In the '035 patent, it recites in the  
11 independent claim the presence of the --

12 THE COURT: This is where I started getting lost  
13 in your briefings. I mean, each one of them sound quite  
14 similar. So if I say the first patent, the '346, is enough,  
15 does that, in your view, automatically say the Claim 1 -- in  
16 other words, when you create these patent thickets, each one  
17 is slightly different, and it's very confusing for a judge  
18 trying to walk through the differences.

19 MR. BUNIS: Your Honor --

20 THE COURT: So why wouldn't Claim 1 pick this up?

21 MR. BUNIS: So it does. Claim 1 of the '346 alone  
22 doesn't, but it does -- let me try to explain it this way:  
23 Certain portions of the dependent claims in the first set of  
24 patents pick up or capture the concepts that are claimed in  
25 the subsequent patent. So, for example, in dependent

1 Claim 3 of the '346, Judge, you have the claiming of the PET  
2 scan, and you name the functional image. In Claim 1, it  
3 just talks about functional, but in Claim 3 you're talking  
4 about the specific type of functional image. So to the  
5 extent the Court is concerned, "How do I manage all these  
6 various claims and nuances --"

7 THE COURT: There are so many claims and so many  
8 patents. I'm not going to go through each claim.

9 MR. BUNIS: So long as you consider all of the  
10 claims, both independent and dependent, you'll be fine  
11 looking at the '346, and you can use that. It may be  
12 clearer if you look at some of the other independent claims  
13 of the other -- I guess there's three patents -- because  
14 they are more specific with respect to what's going on. But  
15 conceptually, Judge, so long as you can appreciate that even  
16 Claim 1 of the '346 claims a multistep process whereby the  
17 claims include looking at the images of the patient, applying  
18 to those anatomical images machine learning in the form of  
19 convolutional neural networks that makes determinations  
20 based on having been trained on thousands of previous images  
21 about where a map should be drawn, and then actually  
22 produces that 3D visualization. It actually creates  
23 something.

24 Now, if you look at those cases that the defendants  
25 cite, those are cases standing for the proposition that

1 simply reading data in one form and spitting it out in  
2 another form -- if you read tabular data and then show it as  
3 a graphic, if you read data in the form of -- for example,  
4 in the *AI Visualize* case, all the claim was directed to  
5 there was taking a look at whether some particular frames  
6 were present locally in the database that the computer was  
7 reading; and if they weren't present locally, then the  
8 patent claims sending a version, a lighter version of those  
9 frames to the client or to the computer.

10 THE COURT: But why did you flag the '141? Is  
11 that because it was just --

12 MR. BUNIS: It's just a little more specific with  
13 respect to -- it would make it easier for the Court to sort  
14 of see what specifically was going on.

15 THE COURT: Because this involves the prostate,  
16 right?

17 MR. BUNIS: Correct, Judge. That's right.

18 THE COURT: And you have other ones that include  
19 the, I don't know --

20 MR. BUNIS: That's right, Judge. Like, the  
21 prostate is a perfect example because what you're able to  
22 do --

23 THE COURT: But there's nothing new about the  
24 prostate that isn't provided in the first one, right?

25 MR. BUNIS: Well, no. I mean, for the purposes of

1 this analysis, why I'm reluctant to say "no" is because I  
2 don't like that -- for the purposes of the 101 analysis, the  
3 answer is "no."

4 THE COURT: Okay, for the purposes of 101. I  
5 mean, there may be different things that are --

6 MR. BUNIS: That's right.

7 THE COURT: Okay.

8 MR. BUNIS: Judge, I just want to leave you with  
9 this understanding that like you did in the *Ocean* case,  
10 right, when the claim is simply directed to collecting images  
11 or collecting data, filtering the data, and then making a  
12 determination based on that filtration, that filtering step,  
13 that's not enough, right? That's not what's going on here.  
14 The claims are very clear: You look at images. You apply  
15 machine learning in the form of convolutional neural networks  
16 to those images. Then you create something -- or you also  
17 consider functional images when you're creating the risk  
18 map, and then you produce something that is a tool that is a  
19 very practical solution to a technical problem that existed  
20 and was identified in the prior art.

21 And to be clear, Judge, yes, radiologists were  
22 conducting these segmentations, but they were doing so, just  
23 as you -- I don't want to presume. I got the impression,  
24 Judge, in the beginning that you were holding one image in  
25 one hand and one in the other and comparing. That's what

1 the prior art describes, right? This claim is not simply  
2 automation of the prior art. It produces something new that  
3 never existed before.

4 THE COURT: All right, thank you.

5 Do you want to, Ms. Pirozollo, respond with five  
6 minutes?

7 MS. PIROZOLLO: Yes. I can respond briefly, your  
8 Honor, because I know Ms. Butler, I know that we have our  
9 other aspect --

10 THE COURT: We do have another aspect.

11 MS. PIROZOLLO: So just three quick points. So,  
12 first of all, in response to the question you asked me  
13 earlier, the *AI Visualize* case did involve 3D virtual views,  
14 and it said the creation of 3D virtual views was still an  
15 abstract idea, abstract data manipulation. So that's my  
16 first point.

17 The second point is, Mr. Bunis referred to machine  
18 learning and the benefits of using machine learning over  
19 subjective analysis of medical images, and your Honor asked  
20 about where are the rules, who trained the AI? You know,  
21 and the answer to that question is, there is no information  
22 about the machine learning claimed, in the claims or in the  
23 patent itself. If you look at Column 25 of the '346 patent  
24 at Lines 32 to 35, so that's three lines of the patent --

25 THE COURT: Wait. I've got to get there.

1 MS. PIROZOLLO: Okay.

2 THE COURT: What column?

3 MS. PIROZOLLO: It's Column 25, Lines 33 to 35.

4 THE COURT: I have so many patents here.

5 (Pause.)

6 THE COURT: Okay, line?

7 MS. PIROZOLLO: 33, the word says "Other  
8 approaches." And it says, "Other approaches based on  
9 machine learning techniques -- e.g., artificial neural  
10 networks (ANNs), e.g., convolutional neural networks (CNNs) --  
11 may also be used." That is the total description of AI that  
12 appears in this patent. As Mr. Bunis conceded, convolutional  
13 neural networks and artificial neural networks were already  
14 known. The patent doesn't teach anything new about machine  
15 learning or neural networks. It has that very limited  
16 disclosure. And the claims don't require any specific  
17 machine learning, and there's no description of any specific  
18 training on medical images that appears in this patent.

19 So the limitation of "use machine learning" is  
20 really just the same thing as "use a computer." There's no  
21 specific rules or information about the machine learning in  
22 the patent or the claims, and that isn't permissible, and  
23 we've cited some cases on that. This is an issue that's  
24 coming up more recently with AI, but we cited the *Power*  
25 *Analytics* case which was affirmed by the Federal Circuit,

1 which held that just adding machine learning to a claim  
2 doesn't turn an abstract idea into a patentable invention.

3 I didn't want to go back to the *Diehr* case, but  
4 very unlike the *Diehr* case, which had a specific equation in  
5 the claims, these claims don't have any specific rules.  
6 They just say "use machine learning," which is the same  
7 thing as saying "use a computer," which *Alice* says you can't  
8 do. And the problem is, one company shouldn't get a patent  
9 to use of machine learning to analyze medical images.  
10 That's just not permissible under *Alice*.

11 And, lastly, I will just say we agree with you  
12 that there is no difference for the 101 analysis between the  
13 '346 and the '141 patent. The issues Mr. Bunis was pointing  
14 to --

15 THE COURT: They both rise or fall?

16 MS. PIROZOLLO: It's the same thing. The more  
17 specifics that Mr. Bunis referred to are things that were in  
18 the prior art. The different types of medical images are  
19 the same types of medical images that we talked about in  
20 connection with the '346 patent. CAT scans, PET scans,  
21 these are all things that have been used. As you pointed  
22 out, prostate cancer, different cancers, you know, this type  
23 of technology doesn't add anything inventive to the claims.  
24 References to radiopharmaceuticals don't add anything to the  
25 claims. The Background of the Invention section of the

1 patents talks about radiopharmaceuticals being known. So  
2 the issues are all the same on these patents. They're all  
3 directed to, and this includes the '817 patent, to the  
4 abstract idea of using machine learning to analyze medical  
5 images.

6 THE COURT: All right, thank you. Let's move on  
7 to Part B. Did you want two seconds?

8 MR. BUNIS: Just two seconds, Judge, very quickly.  
9 Number one, I want to point out the fact that Ms. Pirozollo  
10 mentioned that there's no further description or analysis of  
11 what it means to use convolutional neural networks. That's  
12 a problem for claim construction, Judge. A person of  
13 ordinary skill in the art would understand what it is when  
14 they read CNN in the specification. But, your Honor, we're  
15 way before that. All right, that's number one.

16 And number two, Judge, the cases that say that 3D  
17 imaging is not enough, that's because those are cases where  
18 the patent claim is directed to just the presentation in the  
19 3D form of a re-formation, a reformatting of the data that  
20 was evaluated. That's not what's going on here. The images  
21 are considered in the claims; then the machine learning is  
22 applied, and something new is created by virtue of applying  
23 that machine learning, and you're creating a 3D visualization  
24 that never existed before in any form. It's not a  
25 reformatting of that. We're not claiming, you know, math.

1 We're not claiming to occupy or preempt all applications of  
2 a machine learning to medical images. No. We're very  
3 specifically targeting a solution to applying machine  
4 learning to a situation and producing something that didn't  
5 exist before.

6 THE COURT: Thank you. All right, we need to move  
7 on to the next thing. So maybe if the two of you turn off  
8 your computers and we just go to the new folks up at bat, it  
9 would be really helpful, although I don't want you to leave  
10 because my favorite topic is going to be at the end, which  
11 is potential settlement. So there we go.

12 MS. BUTLER: All right, are you ready for me to  
13 proceed?

14 THE COURT: Yes.

15 MS. BUTLER: Okay. So the discussion that you  
16 just heard --

17 THE COURT: Mr. Bunis, turn off so -- you're not  
18 arguing on this, right, Mr. Bunis? All right, so just  
19 turning off your video would be great. Perfect. Now I've  
20 got the two of you.

21 MS. BUTLER: Good morning, your Honor. Marla  
22 Butler for MIM Software. So the discussion that you just  
23 heard was about four of the patents, and we're moving to  
24 dismiss those patents on 101 grounds. This discussion  
25 relates to the other three patents where we didn't move to

1 dismiss under 101, but we're moving to dismiss for failure  
2 to state a claim.

3 So plaintiffs purport to accuse four MIM products  
4 of accusing (Sic) seven patents, and the four MIM products  
5 at issue are Contour ProtegeAI, SurePlan MRT, LesionID, and  
6 LesionID Pro. And the complaint is long with a lot of  
7 quotes from articles and websites and product literature,  
8 and purports, your Honor, to address a representative claim  
9 from each patent on an element-by-element basis. So that's  
10 important because that's what the complaint purports to do.  
11 It walks through, purportedly, each element of each claim.

12 What the complaint actually does is, for any  
13 representative claim, because they use a representative  
14 claim for each of the patents, address one or more products  
15 as to some limitations and other products as to other  
16 limitations of a claim. So, for example, just as an  
17 example, in their allegations with respect to representative  
18 Claim 1 of the '508 patent, for the first claim limitation --

19 THE COURT: Wait a minute. Whoa. I'm sitting  
20 here with piles of patents, so -- so where do you want me to  
21 be?

22 MS. BUTLER: And I don't need it. For purposes at  
23 this point, your Honor, this is just as an example, and I  
24 think you'll understand why I say I don't even think you  
25 need to look at the claim because I'm not going to get into

1 the meat of what the claim says at this point. But I just  
2 want you to understand that they use this patchwork pleading  
3 where -- so, for example, for the '508 patent, for the first  
4 limitation, Progenics addresses LesionID but says nothing  
5 about the other three products, right? They don't address  
6 Contour ProtegeAI, SurePlan MRT, or LesionID Pro at all.

7 And then they get, for example, to the fourth  
8 limitation, and they do the opposite. So in the complaint  
9 they're putting out these facts that address SurePlan MRT,  
10 Contour ProtegeAI, and LesionID Pro, but they say nothing  
11 about LesionID. And when I say that they addressed these  
12 particular products, I don't mean that they've adequately  
13 alleged infringement. All I mean is that they pointed to  
14 some document or article that mentions the product. And so  
15 the result is that for each asserted claim in the patent  
16 where they pick a representative claim for each patent, they  
17 make no attempt to show that all four products practice all  
18 the claim elements.

19 THE COURT: Can I say this: The Federal Circuit  
20 law on this is not so crystal clear. In other words, they  
21 think it's pretty standard Federal Circuit law that you  
22 don't have to go limitation by limitation.

23 MS. BUTLER: So -- and this is -- and a hundred  
24 percent I agree with you, but I don't think that that means  
25 that a plaintiff can waive, completely fail to address, a

1 claim limitation, especially, your Honor, in a situation  
2 like this where the plaintiff does purport, if you look at  
3 how they laid out their complaint, does purport to address  
4 each claim on an element-by-element basis. So while the  
5 Federal Circuit has certainly said that a plaintiff does not  
6 need to plead infringement on an element-by-element basis,  
7 what the Federal Circuit has also said and what *Iqbal*  
8 directs is that --

9 THE COURT: So you think this is another example  
10 of Federal Circuit -- I mean, that's the thing, is that  
11 *Iqbal* has been applied across many fields but somehow hasn't  
12 hit the Federal Circuit yet.

13 MS. BUTLER: Understood, but I think that they do  
14 make sense together, right? Because what *Iqbal* says is that  
15 the plaintiff has to plead factual content that allows the  
16 court to draw a reasonable inference that the defendant is  
17 liable; here, for infringement. And of course, to infringe,  
18 a product has to meet all elements of the claim of the  
19 asserted patent --

20 THE COURT: -- each limitation, so it's  
21 complicated.

22 MS. BUTLER: I agree it's complicated, but here is  
23 why I don't think in this case it's that complicated,  
24 because the plaintiff purports to walk the Court through  
25 every single element of every single claim, right? But for

1 some of those elements, the plaintiff has done a big kind of  
2 hand wave or just said that they addressed the element; but  
3 when you actually look at what they pled, they haven't  
4 addressed the element. And in that type of situation where  
5 the plaintiff says the accused products -- and I'll try to  
6 give you an example of this -- the accused products perform  
7 Element A of Claim 1 of this patent, and then they cite  
8 literature for two of the four accused products but they  
9 leave the other two, they just completely ignore the other  
10 two, and then the accused products perform Element B of  
11 Claim 1, and now they're going to cite literature for two  
12 different products, right? So what the plaintiff has done  
13 is build this fabric of allegations that has obvious holes  
14 in it. And when those obvious holes are present, when the  
15 plaintiff purports to address the claims on a element-by-  
16 element basis, the Court cannot draw a reasonable inference  
17 that those elements that they don't address, at least for  
18 some products -- here, for the three patents that I'll  
19 address here for all products -- the Court can't draw a  
20 reasonable inference that there is infringement. And  
21 certainly when the plaintiff alleges facts that are the  
22 opposite of what the claim requires, the Court can't draw  
23 such an inference in that situation either.

24 And as to this last point, with the Court's  
25 permission, I'd like to address the '508 patent first, if

1 that's okay. And so that is 11,657,508. It was Exhibit 5 --

2 THE COURT: I've got it, I've got it. I've got my  
3 binder with all the patents in it. So where do you want me  
4 to go?

5 MS. BUTLER: Very good. So I think they use  
6 representative Claim 1, so it's going to be Claim 1 that  
7 we're going to talk about, but I'm going to call your  
8 attention --

9 THE COURT: Where do you want me to go?

10 MS. BUTLER: I'm going to call your attention to  
11 the very last claim limit of Claim 1. So it's in Column 80  
12 starting at around Line 48. But I want to just, even before  
13 we get to the claim, your Honor, I just want to talk about  
14 at a high level what the '508 patent is about, and when the  
15 Court's ready, I'll proceed with that.

16 THE COURT: Okay.

17 MS. BUTLER: So the '508 patent relates to  
18 measuring what's referred to as "radiopharmaceutical  
19 uptake." It's how much of -- and Ms. Pirozollo and  
20 Mr. Bunis talked about injecting these agents, and they bind  
21 to different tissues in the body.

22 THE COURT: Right.

23 MS. BUTLER: Radioactive uptake is just how much  
24 of this agent has bound. So the '508 relates to measuring  
25 radiopharmaceutical uptake in the body. And, for example, a

1 lesion, a cancerous lesion, the purported invention of the  
2 '508 patent is to measure not just the radiopharmaceutical  
3 uptake or the intensity level at the lesion, which the claim  
4 refers to as a "hot spot." So you're not just measuring how  
5 much was absorbed at that lesion, but you're also identifying  
6 reference volumes so that you can compare, right? So  
7 different tissues are going to absorb at different levels.  
8 And so if you have reference volumes of what you expect to  
9 be normal tissue, you can see where the hotspot sits  
10 relative to those reference volumes.

11 And in the '508 patent, and particularly in  
12 representative Claim 1, they're using reference volumes from  
13 the aorta, so blood from the aorta and the liver. And then  
14 what the claim requires, and the point that I pointed you to  
15 starting at about Column 80, Line 48, what the claim  
16 requires is, you determine an index level from the hotspot.  
17 And the way you determine that index level is -- so there's  
18 a -- and I'm going to use an example that's not in the  
19 patent, but I think it does just help to explain what this  
20 patent is about -- there's an industry standard called  
21 PROMISE. And in fact Progenics has a product called  
22 aPROMISE -- this is a small "a" in front of PROMISE --  
23 because they're automating this industry process. And what  
24 it does and what the '508 patent describes is, you know that a  
25 functioning liver, a normal functioning liver would have a

1 higher uptake than the blood pooled in the aorta. And so  
2 the '508 patent and this PROMISE method uses the liver and  
3 the aorta as references. And then you take --

4 THE COURT: Wait a minute. Where does it say --

5 MS. BUTLER: So Column 80 starting at, say, Line 45.  
6 I'm sorry, Line 48.

7 THE COURT: Okay, the aorta and the liver.

8 MS. BUTLER: Right. So at Line 48, "For each  
9 individual detected hotspot, determining a corresponding  
10 individual hotspot intensity level based on the measure of  
11 intensity value at the detected hotspot." So that is  
12 basically, what's the intensity level? How much has that  
13 hotspot absorbed of this radiopharmaceutical agent? And  
14 then determining a corresponding individual hotspot index  
15 level from the hotspot intensity level, the aorta intensity  
16 referenced, or the aorta-referenced intensity level, and the  
17 liver-referenced intensity level.

18 So the way this works, and, for example, in this  
19 PROMISE method, is that you have the, and I've got a sheet  
20 on this, but there's an index from 0 to 2. And because we  
21 know that the liver is expected to be high, that liver is 2.  
22 So anything that's over what the liver's kind of uptake  
23 level, how much that liver has absorbed, would be 2. We  
24 expect the blood aorta to be lower. And so this index is  
25 used to measure where does the hotspot intensity level sit

1 relative to the liver and the aorta?

2 The most important thing here, your Honor, is that  
3 this claim requires using both the liver and the aorta for  
4 the reference values of both of those. But if you look to  
5 what -- well, even before we look to see what Progenics has  
6 alleged here, in addressing this claim element, I'll point  
7 out that Progenics only talks about one product, and that's  
8 the LesionID. This is a perfect good example. They make no  
9 reference, they point to no documents, nothing about Contour  
10 ProtegeAI, SurePlan MRT, or LesionID Pro. And where they --

11 THE COURT: Back up because I don't know this by  
12 heart. So they're claiming that which products violate this  
13 patent, all four or just one?

14 MS. BUTLER: That is the question, your Honor,  
15 because they say that the accused products perform this  
16 particular claim element. They make that statement, but  
17 then they only point to documentation related to one of the  
18 products and point to nothing as to the other three.

19 THE COURT: So you're just saying dismiss the  
20 other three on this claim but keep the one?

21 MS. BUTLER: No. So I'm saying at a minimum for  
22 this claim, the other three should be dismissed, right?

23 THE COURT: So what is the one that they did  
24 allege violated this?

25 MS. BUTLER: LesionID. And here's why we say that

1 even for LesionID, this claim should be dismissed, because  
2 what they point to is documentation, and they quote it in  
3 Paragraph 102 of their complaint.

4 THE COURT: Wait, wait, wait. I don't know this  
5 as well as you do, so let me get to 102.

6 MS. BUTLER: And it starts on, if it helps, Page 55  
7 of the Second Amended Complaint.

8 THE COURT: All right, here we are, 102.

9 MS. BUTLER: And if you scan and if you turn -- so  
10 you see they say the infringing products also possess the  
11 7th limitation, so that kind of broad statement about the  
12 infringing products. For example, MIM Encore's Web page  
13 lists LesionID. They talk about LesionID, use of PERCIST.  
14 It's a method that is used by this particular product. And  
15 then they talk about what PERCIST is, what PERCIST does.  
16 And if you look through the remainder of Paragraph 102, what  
17 they're actually doing is quoting language from the literature  
18 that says that PERCIST doesn't use a reference level for the  
19 aorta or the liver. PERCIST uses the reference -- or excuse  
20 me. They don't say that PERCIST uses --

21 THE COURT: Anyway, you're going too fast for me.  
22 So I'm reading this. So PERCIST, PERCIST isn't a separate  
23 product?

24 MS. BUTLER: It's a method, and they describe it  
25 as a method for measuring tumor burden. It's a method for

1 figuring out kind of the stage of a tumor, for example.

2 THE COURT: Well, it does refer to "and/or aorta  
3 reference."

4 MS. BUTLER: So what is described, if you look at,  
5 for example --

6 THE COURT: I can't do this on a motion to dismiss.  
7 I understand your point about the other products, but it's  
8 saying aorta and liver.

9 MS. BUTLER: So while measurements might be taken  
10 from the aorta and the liver, the index value is determined  
11 from one of them. And Claim 1 of the '508 patent requires  
12 that the --

13 THE COURT: It says "liver and/or."

14 MS. BUTLER: Where are you reading, your Honor?

15 THE COURT: Am I wrong? "Involves, among other  
16 things, comparing lesion peak standardized update values --"  
17 at the very bottom of Page 55 -- "to cut off thresholds  
18 derived from liver and/or aorta reference intensities."

19 MS. BUTLER: So that's what Progenics says, but  
20 then they go on to quote the actual literature that says you  
21 use one or the other. They say --

22 THE COURT: I know. I can't do that on a motion  
23 to dismiss. You may win the ballpark. You're asking too  
24 much of me at this point. I mean, as long as -- I do get  
25 your point about the other three products. That seems fair

1 enough.

2 MS. BUTLER: Understood, understood. So, yes, at  
3 a minimum, where those other three products have not been  
4 addressed at all as to this particular claim element, we'd  
5 suggest they be dismissed. And even for LesionID, and I'll  
6 just make the point last and we can move on to another  
7 patent --

8 THE COURT: Okay.

9 MS. BUTLER: Even for --

10 THE COURT: I don't have that much time to move on  
11 to all the patents, so --

12 MS. BUTLER: Okay, so --

13 THE COURT: But is it the same kind of thing where  
14 you're saying they're making certain claims, but it's  
15 inconsistent with the actual literature? Is that what's  
16 happening here?

17 MS. BUTLER: So in the '508 patent, what they're  
18 alleging, what they point to in the literature in their  
19 allegations is actually the opposite of what the claim  
20 requires.

21 THE COURT: So they make the allegations in the  
22 complaint, but the literature --

23 MS. BUTLER: That they quote, what's actually in  
24 the -- and you don't have to go to the literature. All you  
25 need to do is read the rest of Paragraph 102, right, and the

1     parentheticals that they have in 102 which say, for example,  
2     if the liver is damaged -- you get both, so that if the  
3     liver is damaged, you can use the aorta instead. So I'm not  
4     suggesting that your Honor look at the literature. All I'm  
5     suggesting is that you look at the parentheticals that they  
6     have quoted from the literature, which make it clear that --  
7     so there is, just because I have it underlined, if you are  
8     on Page 56 of the Second Amended Complaint, there is a  
9     parenthetical that says, you know, "the intensity for each  
10    hotspot, which will be compared with liver or aorta  
11    references," right? And about five lines from the bottom on  
12    Page 56, "PERCIST compares the peak SUL intensity for each  
13    hotspot with liver or aorta references."

14             My whole point, your Honor, is that what the claim  
15    requires is that it be compared with liver and aorta. And  
16    when they are saying that the literature says it's "or,"  
17    that's the opposite of what the claim --

18             THE COURT: But then later on they use "and,"  
19    like, later on in the next sentence down.

20             MS. BUTLER: So the next sentence down says, "See  
21    id. When the activity and the descending thoracic aorta is  
22    measured instead --"

23             THE COURT: No, no, the one that says "Retain  
24    those hotspots with SUL peak values above the liver and  
25    aorta-derived thresholds." So I do agree it's confusing.

1 I --

2 MS. BUTLER: Understood. I hear you, your Honor.  
3 I think, and what I would just ask the Court, if you look at  
4 that Paragraph 102, again, while those values might be  
5 measured and even retained, whenever you're talking about  
6 comparing, which is what you're doing with an index, it's  
7 the liver or the aorta, not the liver and the aorta as the  
8 claim requires.

9 THE COURT: Okay, thank you. So at the very  
10 least, I have to be clear, I'm not going to probably -- it's  
11 "when all reasonable inferences" kind of thing. I mean,  
12 it's --

13 MS. BUTLER: Understood.

14 THE COURT: But you're saying the other three  
15 products aren't named?

16 MS. BUTLER: They're not. As to this particular  
17 claim element, they don't address them at all. And where  
18 you address one claim element and purport to say all the  
19 accused products and you've given the Court nothing from  
20 which the Court can infer that these other three products do  
21 the same thing, right, then that claim element hasn't been  
22 met; a plausible claim of infringement has not been met.

23 THE COURT: All right, I will look at that through  
24 this prism.

25 So let me turn to opposing counsel on this.

1           MS. SPIETH: Absolutely, your Honor. Anita Spieth  
2 on behalf of the plaintiff. The Court expressed some  
3 frustration about dealing with the seven patents at this  
4 stage of the case, and I think what you're running into is  
5 the fact that MIM just didn't have 101 arguments for these  
6 three patents, so they're trying to shoehorn them in somewhere  
7 in here, and you'll find that their arguments really just do  
8 not hold up to the 12(b)(6) --

9           THE COURT: The point she just made, though, take  
10 that particular claim. I mean, it does strike me that at  
11 most, we're talking about one product here.

12           MS. SPIETH: So absolutely, your Honor, and that  
13 can be easily swiped away. What is accused in the  
14 complaint -- and you don't have to look now, but for your  
15 record, it's in Paragraphs 5 and I believe 52 of the  
16 complaint -- is a suite of products. So imagine, like, does  
17 your Honor --

18           THE COURT: Wait, wait. There's a reason I have  
19 all of you sitting in front of me. What do you mean a suite  
20 of products?

21           MS. SPIETH: Does your Honor use the Microsoft  
22 Word suite which includes Microsoft Word, Excel? It  
23 includes PowerPoint. It includes Keynote, depending on what  
24 you buy. Are you familiar with the concept, your Honor?

25           THE COURT: The concept, yes. Do I use those?

1 No.

2 MS. SPIETH: That's okay, that's okay. I'm  
3 analogizing to that concept so that it might be more clear.  
4 What is accused is MIM's suite of software, all of which it  
5 sells, all of which it advertises, and all of which can be  
6 bought by MIM customers to do this radiologic imaging task.

7 One customer might turn on a particular module of  
8 that suite and might buy it. I don't know that. That's  
9 something we'll have to uncover through discovery, but what  
10 is accused in this case is the MIM suite of software.

11 THE COURT: I can't do it that way. I have to do  
12 it product by product.

13 MS. SPIETH: Actually, your Honor, I'll tell you  
14 why you can. The product is MIM's product, so when you  
15 think of it in that context, we have endeavored to fast  
16 forward some of the infringement allegations. As MIM points  
17 out, they know exactly what's accused. It's perfectly clear  
18 from the complaint. It certainly meets the *Iqbal* standard  
19 as the *Iqbal* standard has been interpreted by the Federal  
20 Circuit.

21 THE COURT: Well, can I just say, your colleague  
22 listed four specific MIM products; Contour, you know,  
23 et cetera, LesionID, that sort of thing. So each one of  
24 those is a separate product, right?

25 MS. SPIETH: No, your Honor. They're modules.

1 This is where I think you're getting tripped up here by a  
2 factual distinction. They're modules within MIM's software  
3 products, so customers buy multiples of those and use them  
4 together. For example, this is in the complaint --

5 THE COURT: Can you buy them separately?

6 MS. SPIETH: That's for us to learn through  
7 discovery. We don't know the answer to that, but I suspect  
8 the answer is that most of MIM customers use them together.  
9 For example, just to give you a specific example --

10 THE COURT: Why don't you know that? Why don't  
11 you just buy it?

12 MS. SPIETH: I don't believe that --

13 THE COURT: -- collaboration. So, I mean, I don't  
14 know that I --

15 MS. SPIETH: I don't believe that they would sell  
16 it to us, but our complaint alleges in fact that, for  
17 example, one of the products is a part of the other product;  
18 Contour ProtegeAI is a part of MIM's SurePlan MRT.

19 So it's not the case that these are -- so let me put it  
20 in a way that might be easier to understand. MIM cites one  
21 single case for this proposition that you can dismiss, you  
22 know, an allegation of infringement with respect to one  
23 product over another. That was about spray cans. In that  
24 case, the plaintiff listed ten spray cans, but its  
25 allegations were only about one single spray can. So the

1 court said, "Well, you didn't tell me about these other  
2 spray cans. They're totally separate products. I'm going  
3 to dismiss the nine spray cans from the case."

4 Actually, what we have here is a suite of products. We've  
5 identified infringement with respect to all of the products  
6 across the seven accused patents. And in fact what the  
7 Court does when it has exemplary --

8 THE COURT: I'm just trying to -- for example,  
9 given your example, I don't have Excel. I have some Microsoft  
10 products but not others.

11 MS. SPIETH: Right.

12 THE COURT: So they're separate patents. It may  
13 be that you can get a bundle. If you buy them in a certain  
14 way, maybe it's cheaper or something, but they're separate  
15 products. And I do get your point; you don't have to go  
16 limitation by limitation. I don't know whether the Federal  
17 Circuit has read *Iqbal*, but at least right now, you don't  
18 have to go limitation by limitation. So I don't know that I  
19 can say, for example, the example that was just given:  
20 Well, there's enough in the liver/aorta distinction to get  
21 you infringement, but that's going to get you infringement  
22 on all the others in the suite.

23 MS. SPIETH: Well, there is guidance in the case  
24 law, and it's cited in our brief. It's the *Windy City* case,  
25 and then there's an *ASUSTek* case which can give you guidance

1 that exemplary infringement allegations from overlapping  
2 products are sufficient at this stage. And I think what you  
3 have to do is, you have to do it --

4 THE COURT: You're saying they're all the same --  
5 it's different than Microsoft then. Those aren't  
6 overlapping products. You're saying these are overlapping.  
7 It's just like having, oh, I don't know, that you only buy  
8 them in a suite. Is that what you're saying?

9 MS. SPIETH: That is our understanding of how  
10 they're sold is in a suite of products.

11 THE COURT: And where does it say that here in the  
12 complaint?

13 MS. SPIETH: It's in Paragraph 5 of the complaint  
14 says it's a suite of products.

15 THE COURT: Okay, let me get there.

16 (Pause.)

17 MS. SPIETH: And to be clear, your Honor, I don't  
18 know that MIM would sell their products to us.

19 THE COURT: So you here say "Software products  
20 like Contour Protege, MIM's SurePlan, Lesion, the infringing  
21 products." So you're separating them out.

22 MS. SPIETH: So let me also point you to  
23 Paragraph 52 which discusses that the products, those four  
24 infringing products, the Contour ProtegeAI, MIM's SurePlan  
25 MRT, LesionID, and LesionID Pro -- I'm reading from

1 Paragraph 52 which is on Page 16 of the Second Amended  
2 Complaint -- "are part of MIM's broader software suite."

3 THE COURT: Yes, but "Infringing Products" is  
4 capitalized, and then you parenthetical it, which makes me  
5 feel quite clear that each one of them is a separate  
6 product. You're defining them by the parenthetical.

7 MS. SPIETH: And perhaps, you know, this will  
8 become more clear in the infringement contention stage of  
9 the case, which is coming up in a few weeks. And that's the  
10 reason why the burden is not as high at the complaint stage  
11 as it is at the infringement contention stage of the case.

12 THE COURT: Well, can I just ask you this: Assuming  
13 for a minute you've defined each product as four separate  
14 products, I don't think that's an unfair reading of this  
15 complaint, and so what I'm trying to understand is, have you  
16 alleged that it's not all for one or one for all, and you  
17 don't have to go limitation by limitation? But as it was  
18 just shown on the one that we talked about, there may be  
19 enough with respect to one product; but are you just sort of  
20 assuming that because you got it on one, you got it on all  
21 four?

22 MS. SPIETH: So, again, the complaint is laying  
23 out exemplary allegations of infringement that are designed  
24 to meet the *Iqbal* standard, which is to put the defendant  
25 reasonably on notice of the claims and create a plausible

1 entitlement to relief.

2 THE COURT: I get it. So you did that on one.

3 MS. SPIETH: But I want to point out to you that I  
4 think we've been a little quick in saying what's accused  
5 here. LesionID is mentioned for the '508 patent, but  
6 there's also allegations involving Contour ProtegeAI and  
7 MIM's SurePlan MRT, which I can point the Court to --

8 THE COURT: Excuse me. With respect to which  
9 patents?

10 MS. SPIETH: The '508. So if I can just point you  
11 to Paragraph 97, which is talking about the second limitation  
12 of Claim 1 of the '508.

13 THE COURT: Wait. You're going faster than I can  
14 go because I have to get there. You know it by heart and I  
15 really don't. I'm learning. So, all right.

16 MS. SPIETH: Sure. So Page 50, which is part of  
17 Paragraph 97, it quotes from the 510K application, which is  
18 an FDA regulatory application for MIM's Contour ProtegeAI  
19 product. So, in other words, this is explaining how MIM's  
20 Contour ProtegeAI product meets the limitation of the '508  
21 patent. And then continuing --

22 THE COURT: I don't understand that.

23 MS. SPIETH: Yes, continuing on, just so the  
24 record is complete, Paragraph 99 is also about Claim 1 of  
25 the '508 patent, and it's describing how MIM's SurePlan MRT

1 meets the limitation of the '508 patent. There's a quote  
2 from MIM's marketing material for MIM SurePlan MRT.

3 THE COURT: Where does it talk about aortas and  
4 livers?

5 MS. SPIETH: So, again, all of these things work  
6 together. They are designed to work together for MIM's  
7 customers. So MIM can't avoid infringement by saying, "Oh,  
8 well, we only have one piece of software, one piece of the  
9 piece of software that does the liver piece. We have one  
10 piece of the software that does the aorta piece, and we have  
11 another piece of the software that puts all the pieces  
12 together and makes the 3D visualization." They can't get  
13 out of infringement because they call their products by  
14 different tradenames.

15 THE COURT: Well, yes, they can if they -- I mean,  
16 you have to plead something with respect to each product and  
17 each patent, and it's very hard to read. Let me just put it  
18 this way: Usually, in most patent cases, they claim one  
19 product, and then they claim which patent, and so I'm just  
20 having a hard time with this.

21 But, in any event, I will read your brief, and I  
22 will go through each one and see where you've cited to  
23 because it's all about going back to the complaint.

24 MS. SPIETH: And I just point the Court to the  
25 *ASUSTek* and the *Windy City* cases because I think they

1 provide good guidance about exemplary allegations of  
2 infringement where there's multiple products that are  
3 infringed.

4 THE COURT: But don't you just win on that  
5 exemplary product?

6 MS. SPIETH: Yes, yes. In fact, we're being held  
7 to a higher standard because as everyone on this hearing  
8 agrees, there is no obligation to plead infringement element  
9 by element. So I think what's happening here is that the  
10 plaintiffs are being punished for clearing the bar too high.

11 THE COURT: Well, I don't know if that's true. In  
12 any event, I'm not going to go through each one of them now.  
13 I think, unfortunately, you've charged so many patents, it  
14 is making it a burden on the Court to sit and sift through  
15 all of them.

16 MS. SPIETH: Can I respond --

17 THE COURT: I'm going to assume for a minute that  
18 you've been able to -- I'll read the complaint, and I'll  
19 read your motion in opposition to the motion to dismiss. I  
20 am not going to go back into the literature. That's what  
21 I'm not going to do. But it may be that I -- you've defined  
22 accused products as the four of them, and so I'm going to  
23 look at them. And if it doesn't work, it will be without  
24 prejudice to your amending. So that's how it will go. And  
25 I can't really go through each one of them here now. We're

1 already close to noon. So if you're sensing some -- I will  
2 look through every -- in your motion to dismiss, your  
3 opposition to the motion to dismiss, I will go through each  
4 claim. And I will not micromanage it, I will not go  
5 limitation by limitation, but you at the very least have to  
6 make it plausible, based on what I've read. So that's what  
7 I'm going to do.

8 Can I just have everyone back on now. I know you  
9 were talking in terms of -- and maybe go off the record here  
10 for settlement discussions.

11 (Discussion off the record.)

12 THE COURT: All right, thank you very much, and  
13 have a nice lunch.

14 MS. PIROZOLLO: Thank you, your Honor.

15 MR. BUNIS: Thank you, your Honor.

16 MS. SPIETH: Thank you, your Honor.

17 MS. BUTLER: Thank you, your Honor.

18 THE COURT: Bye-bye.

19 (Adjourned, 12:05 p.m.)  
20  
21  
22  
23  
24  
25

C E R T I F I C A T E

1  
2  
3 UNITED STATES DISTRICT COURT )  
4 DISTRICT OF MASSACHUSETTS ) ss.  
5 CITY OF BOSTON )

6  
7 I, Lee A. Marzilli, Official Federal Court  
8 Reporter, do hereby certify that the foregoing transcript,  
9 Pages 1 through 66 inclusive, was recorded by me  
10 stenographically at the time and place aforesaid in CA  
11 No. 24-10437-PBS, Progenics Pharmaceuticals, Inc., et al v.  
12 MIM Software Inc., and thereafter by me reduced to  
13 typewriting and is a true and accurate record of the  
14 proceedings.

15 Dated this 5th day of November, 2024.

16  
17  
18  
19  
20 /s/ Lee A. Marzilli

21 \_\_\_\_\_  
22 LEE A. MARZILLI, CRR  
23 OFFICIAL COURT REPORTER  
24  
25